What Is 7-OH (7-Hydroxymitragynine)? Effects & Risks

7-hydroxymitragynine, known as 7-OH or 7oh, is a potent opioid receptor agonist derived from the kratom plant.

7-OH binds to the same mu-opioid receptors as morphine and heroin. Commercial products concentrate this compound at levels up to 98% purity through semi-synthetic chemical manufacturing.

These products, sold as gummies, tablets, liquid shots, and powders, are fundamentally different from whole-leaf kratom and carry significantly higher risks of dependence and respiratory depression.

Understanding what 7-OH is and why federal regulators are moving to restrict concentrated products is critical for anyone who has used them or is helping a loved one who has.

Key Takeaways

• According to a 2004 study published in Life Sciences by Matsumoto et al., 7-hydroxymitragynine is 13 times more potent than morphine in antinociceptive assays, and the FDA’s 2025 scientific assessment confirmed it produces respiratory depression at more than 3 times the potency of morphine.
• CDC MMWR data show kratom-related poison control calls surged from fewer than 100 in 2014 to more than 1,600 in 2024, with 233 kratom-associated deaths reported between 2015 and 2024 (Holstege et al., 2026).
• Concentrated commercial 7-OH products contain up to 98% pure 7-hydroxymitragynine, compared to less than 0.02% found naturally in kratom leaf, making them orders of magnitude more potent than leaf tea.
• In July 2025, the FDA formally recommended Schedule I classification for concentrated 7-OH products and issued 7 warning letters to manufacturers, citing documented overdose deaths and opioid-equivalent abuse potential.
• 7-hydroxymitragynine produces physical dependence, tolerance, and withdrawal symptoms that meet DSM-5 criteria for opioid use disorder (OUD), confirmed in a 2025 case series published in the Journal of Addiction Medicine (Smith et al., 2025).

What Is 7-Hydroxymitragynine (7-OH)?

7-hydroxymitragynine (7-OH) is a terpenoid indole alkaloid found in trace amounts in Mitragyna speciosa (kratom) that acts as a partial agonist at mu-opioid receptors, producing opioid-like analgesia, euphoria, and physical dependence.

7-OH in Natural Kratom vs. Commercial Products

7-hydroxymitragynine occurs naturally in kratom leaves at less than 0.02% of dry leaf weight, but commercial products manufacture it semi-synthetically at concentrations up to 98% purity.

Natural kratom leaf alkaloid composition:

• Mitragynine: comprises 1 to 2% of dry leaf weight and serves as the dominant active alkaloid; CYP3A4 liver enzymes convert a fraction into 7-OH through hepatic oxidation, naturally limiting the total 7-OH produced
• 7-Hydroxymitragynine: present at less than 0.02% of dry leaf weight and self-limiting in concentration because formation depends entirely on metabolic conversion from mitragynine
• Minor alkaloids: speciociliatine, speciogynine, paynantheine, corynantheidine, and speciofoline comprise the remaining active alkaloid profile; most have poorly characterized pharmacology at opioid receptors

Commercial 7-OH products differ entirely from leaf preparations:

• Semi-synthetic production: bulk mitragynine undergoes chemical mono-oxidation, yielding isolated 7-OH at concentrations up to 98% purity with no equivalent in nature
• Product forms: sublingual tablets (5 to 22 mg 7-OH per tablet), gummies, liquid shots, powders, and dissolvable strips distributed through gas stations, smoke shops, and online retailers
• Bypassed liver metabolism: oral and sublingual delivery routes bypass hepatic first-pass conversion, delivering concentrated 7-OH doses directly to systemic circulation at levels the body cannot reach through leaf ingestion

How 7-OH Is Classified

7-hydroxymitragynine is classified by the FDA as “a predominant mu-opioid receptor agonist and an emerging opioid threat,” despite being structurally distinct from opium-derived compounds.

Key classification distinctions:

• Opiate vs. opioid: 7-OH is not an opiate (not derived from the opium poppy) but is an opioid because it binds and activates opioid receptors in the brain and spinal cord
• Receptor activity profile: partial agonist at mu-opioid receptors (MOR), competitive antagonist at kappa-opioid receptors (KOR), and weak antagonist at delta-opioid receptors (DOR)
• Federal regulatory status (April 2026): kratom and 7-OH remain federally unscheduled; the FDA recommended Schedule I classification for concentrated 7-OH in July 2025, with DEA rulemaking still in progress and no scheduling date confirmed

How 7-OH Binds Opioid Receptors in the Brain

7-hydroxymitragynine activates mu-opioid receptors in the brain and spinal cord with a binding affinity ranging from 7.2 to 70 nM, producing dose-dependent analgesia, sedation, euphoria, and respiratory depression through the same receptor pathway as prescription opioids.

The CYP3A4 Metabolic Pathway

Mitragynine undergoes hepatic oxidation via cytochrome P450 3A4 (CYP3A4) enzymes to form 7-hydroxymitragynine, but concentrated commercial products bypass this rate-limiting metabolic step entirely.

A review of how opioids affect the brain through mu-opioid receptor activation clarifies why concentrated 7-OH produces far more intense effects than leaf ingestion through this same CYP3A4 pathway.

The conversion and activation sequence:

• Step 1: Mitragynine consumed orally enters hepatic portal circulation after intestinal wall absorption
• Step 2: CYP3A4 enzymes in the liver oxidize a fraction of mitragynine into 7-hydroxymitragynine at a rate constrained by enzyme availability
• Step 3: 7-OH crosses the blood-brain barrier and binds mu-opioid receptors in the periaqueductal gray, rostral ventromedial medulla, and spinal dorsal horn, producing analgesia and sedation
• Step 4: In human plasma, 7-OH undergoes further enzymatic conversion to mitragynine pseudoindoxyl (MP), a metabolite 31 times more potent than 7-OH at the mu-opioid receptor and approximately 400 times more potent than mitragynine
• Critical risk: commercial products deliver pre-formed 7-OH directly, triggering downstream MP formation at concentrations the body cannot generate through leaf ingestion under any circumstances

G-Protein Biased Agonism and Beta-Arrestin-2

7-hydroxymitragynine exhibits G-protein biased agonism at the mu-opioid receptor, activating analgesic and euphoric signaling pathways without measurably recruiting the beta-arrestin-2 cascade.

What this distinction means clinically:

• Classical opioids such as morphine and fentanyl: activate G-protein signaling (producing analgesia and euphoria) and recruit beta-arrestin-2, which mediates tolerance, respiratory depression, and constipation
• 7-OH and mitragynine: activate G-protein pathways with no measurable beta-arrestin-2 recruitment in standard laboratory assays, classifying them as “atypical opioids” (Kruegel et al., 2016)
• The key limitation of this distinction: G-protein bias does not prevent respiratory depression at high concentrated doses; the FDA’s 2025 assessment confirmed 7-OH produces respiratory depression at greater than 3 times the potency of morphine in controlled conditions
• Cross-tolerance: repeated 7-OH administration produces tolerance that crosses fully with morphine, confirming complete mu-opioid receptor neuroadaptation regardless of the beta-arrestin signaling difference

Dose-Dependent Effects on the Central Nervous System

7-hydroxymitragynine produces effects that shift from stimulant-like to opioid-sedative as dose increases, following the same dose-response curve seen with kratom leaf but at significantly lower absolute quantities due to higher bioavailability.

At low concentrations (1 to 5 mg extracted 7-OH equivalent), 7-OH activates:

• Adrenergic receptors: producing increased alertness, energy, and reduced fatigue
• Dopaminergic reward pathways: generating mild euphoria, mood elevation, and motivation enhancement
• Peripheral mu-opioid activity: mild analgesia without significant sedation or respiratory concern

At high concentrations (above 10 mg extracted 7-OH), receptor saturation shifts effects to:

• Profoundly centrally mediated analgesia combined with heavy sedation
• Intense euphoria with strong reinforcement potential that drives compulsive dosing
• Nausea, vomiting, gastrointestinal slowing, and pinpoint pupils (miosis)
• Dose-dependent respiratory depression carrying maximum danger at high doses or in combination with any central nervous system depressant

7-OH Potency Compared to Kratom and Other Opioids

7-hydroxymitragynine is 13 times more potent than morphine in antinociceptive assays and produces respiratory depression at more than 3 times the potency of morphine, placing concentrated 7-OH products in a meaningfully higher danger category than whole-leaf kratom or standard pharmaceutical opioids at equivalent doses.

Substance	Potency vs. Morphine	MOR Binding (Ki)	Federal Legal Status (April 2026)	Respiratory Depression Risk
7-OH (concentrated)	13x more potent	7.2 to 70 nM	Unscheduled (Schedule I pending)	High (more than 3x morphine)
Morphine	Reference standard	~3.5 nM	Schedule II	High
Mitragynine (kratom leaf)	Weaker than morphine	~277 nM	Unscheduled	Low to moderate
Codeine	~0.1x morphine	~1,000 nM	Schedule II/V	Low
Fentanyl	50 to 100x more potent	~0.5 to 1 nM	Schedule II	Very high
Mitragynine pseudoindoxyl (MP)	~400x mitragynine	~1.7 nM	Unscheduled	Very high

Natural vs. Concentrated 7-OH: A Risk Multiplier

Concentrated 7-OH products deliver 7-hydroxymitragynine at levels approximately 5,000 times higher than naturally occurring concentrations in dried kratom leaf, fundamentally changing the risk and dependence profile of the substance.

Key concentration comparisons by product type:

• Natural kratom leaf: less than 0.02% 7-OH by dry weight; total absorbed 7-OH constrained by CYP3A4 conversion rate and enzyme availability
• Kratom extract powders: 2 to 5% 7-OH equivalent; partial concentration with some hepatic bypass
• Commercial 7-OH tablets: 5 to 22 mg pure 7-OH per serving, produced via chemical synthesis and delivered pre-formed to systemic circulation
• Pharmaceutical-grade semi-synthetic 7-OH: up to 98% purity, representing concentrations approximately 5,000 times those found in dried kratom leaf

Drug Interactions That Amplify 7-OH Danger

7-hydroxymitragynine inhibits CYP3A4 and CYP2D6 enzymes, increasing plasma concentrations of co-administered drugs that rely on these pathways and producing synergistic toxicity with central nervous system depressants.

Dangerous combinations confirmed in poison-control and medical examiner data:

• 7-OH plus alcohol: additive CNS and respiratory depression; multiple cardiac arrest cases documented in Los Angeles County Medical Examiner records
• 7-OH plus benzodiazepines: synergistic respiratory depression; the opioid-benzodiazepine combination drives the majority of overdose deaths in the United States
• 7-OH plus diphenhydramine (Benadryl): additive sedation and respiratory suppression documented in fatal overdose cases involving otherwise healthy adults aged 18 to 40
• 7-OH plus kava: amplified hepatotoxicity risk; both compounds carry independent drug-induced liver injury signals
• 7-OH plus SSRIs or SNRIs: kratom alkaloids interact with serotonergic and adrenergic receptors, increasing serotonin syndrome risk in individuals already taking antidepressants
• 7-OH plus warfarin or anticonvulsants: CYP3A4 inhibition by kratom alkaloids elevates plasma levels of narrow therapeutic-index drugs, producing unpredictable toxicity

For individuals managing fentanyl dependence alongside 7-OH use, both conditions share mu-opioid receptor neuroadaptation and require integrated polydrug clinical planning.

Risks and Side Effects of 7-OH

7-hydroxymitragynine produces adverse effects ranging from nausea and constipation at low doses to respiratory failure, coma, and death at high doses or in combination with other central nervous system depressants.

Common Side Effects of 7-OH

7-hydroxymitragynine consistently produces these adverse effects at moderate doses across self-report surveys, clinical case reports, and poison-control documentation.

Common adverse effects reported across user and clinical data:

• Nausea and vomiting: dose-dependent and more frequent with sublingual tablets and liquid shots than leaf preparations, due to higher bioavailability and faster onset
• Constipation: mu-opioid receptor activation in the gastrointestinal tract slows intestinal motility through the same mechanism as prescription opioids, producing significant GI discomfort with regular use
• Dizziness and sedation: particularly pronounced above 5 mg extracted 7-OH equivalent, impairing driving, operating machinery, and complex cognitive tasks
• Heart rate dysregulation: tachycardia at low doses that transitions to bradycardia at high doses, reflecting the dose-dependent shift from adrenergic stimulation to opioid sedation
• Itching and sweating: histamine release and adrenergic receptor activity common to mu-opioid agonism at any potency
• Dry mouth, headache, and cognitive slowing: consistent with adrenergic and opioid receptor interactions; reported across user surveys and clinical case series

Severe Effects and Overdose Risk from 7-OH

7-hydroxymitragynine overdose produces opioid toxidrome including respiratory depression, pinpoint pupils, loss of consciousness, and cardiovascular collapse, requiring immediate emergency intervention.

Call 911 immediately and administer naloxone if any of the following occur:

1. Breathing has slowed to fewer than 12 breaths per minute, become irregular, or stopped entirely
2. Blue, gray, or pale discoloration of the lips, fingernails, or fingertips (cyanosis)
3. Unresponsive to voice, shaking, or sternal rub
4. Pinpoint pupils (miosis) combined with sedation or unconsciousness
5. Seizure activity: convulsions, rigid limbs, or loss of bladder or bowel control
6. Choking, gurgling, or snoring sounds indicating airway obstruction

Additional overdose risk factors that require awareness:

• Polydrug use: any 7-OH product combined with alcohol, benzodiazepines, or antihistamines dramatically amplifies fatal overdose probability through synergistic CNS depression
• Product mislabeling: commercial 7-OH carries no mandatory quality control; actual potency routinely exceeds labeled content, making dose estimation unreliable
• Naloxone half-life gap: 7-OH has a half-life of approximately 5.75 hours while a single naloxone dose lasts only 30 to 90 minutes, meaning repeat naloxone doses or a continuous hospital infusion may be required to prevent respiratory depression recurrence

Long-Term Health Consequences of 7-OH Use

Chronic 7-hydroxymitragynine exposure produces neurobiological changes consistent with opioid use disorder (OUD), including mu-opioid receptor downregulation, tolerance, physical dependence, and structural alterations in reward circuitry.

Long-term consequences documented in clinical and epidemiological literature:

• Opioid use disorder (OUD): DSM-5 criteria for OUD apply directly to 7-OH dependence; a 2025 case series published in the Journal of Addiction Medicine confirmed DSM-5-qualifying substance use disorder from a synthetic 7-OH sublingual product (Smith et al., 2025)
• Drug-induced liver injury (DILI): kratom alkaloids including mitragynine and 7-OH produce acute hepatotoxicity in reported cases; elevated liver enzymes (ALT, AST) and cholestatic patterns are documented with chronic high-dose use
• Cognitive impairment: mu-opioid receptor downregulation in the prefrontal cortex impairs working memory, executive function, and emotional regulation with sustained 7-OH exposure
• HPA axis suppression: chronic opioid agonism suppresses the hypothalamic-pituitary-adrenal (HPA) axis, reducing testosterone and cortisol production and disrupting hormonal regulation over time
• Co-occurring mental health deterioration: research published in The Primary Care Companion for CNS Disorders found 26.7% of kratom users reported a past-year major depressive episode (MDE) (Schimmel et al., 2021)

Individuals experiencing these consequences alongside recognized signs of substance addiction should pursue a professional DSM-5 evaluation to determine the appropriate level of clinical intervention.

7-OH Addiction, Withdrawal, and When to Seek Help

Abrupt 7-hydroxymitragynine cessation triggers opioid withdrawal syndrome within 6 to 24 hours of the last dose, producing symptoms across three distinct phases that can extend weeks to months for heavy users.

Signs of 7-OH Physical Dependence

7-hydroxymitragynine produces physical dependence through mu-opioid receptor downregulation and compensatory noradrenergic hyperactivity, following the same neurobiological pathway as prescription opioids.

Signs that physical dependence on 7-OH has developed:

• Tolerance: requiring progressively larger 7-OH doses to achieve the same pain relief, euphoria, or functional stability
• Dose escalation: inability to remain at a stable amount despite a stated intention to reduce use
• Failed cessation attempts: multiple unsuccessful efforts to stop or cut back use without medical support
• Morning dosing: consuming 7-OH first thing in the morning to prevent withdrawal symptoms rather than for any recreational or pain-relief purpose
• Continued use despite documented harm: persisting despite nausea, liver enzyme abnormalities, financial strain, or relationship consequences

Individuals concerned about these patterns can review opioid use disorder diagnostic criteria to identify whether a professional clinical assessment is warranted.

7-OH Withdrawal Timeline

7-hydroxymitragynine withdrawal follows a three-phase trajectory driven by the compound’s approximately 5.75-hour half-life and the degree of mu-opioid receptor downregulation accumulated over the period of use.

Phase 1: Acute Withdrawal (Hours 6 to 72)

• Onset: 6 to 12 hours after last dose; faster than heroin withdrawal due to 7-OH’s shorter half-life
• Peak intensity: 24 to 48 hours after last dose
• Symptoms include: severe muscle aches, profuse sweating, yawning, rhinorrhea, diarrhea, nausea, vomiting, tachycardia, insomnia, agitation, and intense 7-OH cravings
• Mechanism: noradrenergic rebound from mu-opioid receptor downregulation drives locus coeruleus hyperactivation, producing the characteristic anxiety and autonomic storm of opioid withdrawal

Phase 2: Sub-Acute Withdrawal (Days 4 to 21)

• Severity: diminishing but functionally impairing; most relapse events occur during this phase when acute distress fades but psychological symptoms persist
• Symptoms include: persistent insomnia, low-grade anxiety, irritability, fatigue, reduced appetite, cognitive fog, and mood instability
• Duration: typically 1 to 3 weeks; longer for daily high-dose users or those with co-occurring anxiety disorders

Phase 3: Post-Acute Withdrawal Syndrome (Weeks to Months)

• Defining feature: anhedonia from opioid receptor downregulation in the nucleus accumbens and prefrontal dopaminergic circuits, producing an inability to feel pleasure without 7-OH
• Symptoms include: persistent anxiety or depression, difficulty concentrating, and intermittent cravings triggered by environmental or emotional cues
• Clinical relevance: PAWS extends the required monitoring window and makes continued outpatient care essential for sustained recovery from 7-OH dependence

When to Seek Emergency Medical Care During Withdrawal

Certain 7-OH withdrawal presentations require emergency medical intervention and cannot be safely managed outside a clinical setting.

Seek immediate emergency care if withdrawal produces any of the following:

1. Seizures or convulsions: abrupt cessation of high-dose 7-OH carries seizure risk through sudden compensatory GABA and noradrenergic rebound
2. Severe dehydration from vomiting or diarrhea: electrolyte imbalances from sustained fluid loss can cause life-threatening cardiac arrhythmia
3. Chest pain or irregular heartbeat: adrenergic hyperactivity during opioid withdrawal stresses the cardiovascular system, particularly in individuals with pre-existing cardiac conditions
4. Suicidal ideation or intent: opioid withdrawal-associated anhedonia dramatically elevates suicide risk, especially in individuals with co-occurring major depressive disorder or borderline personality disorder
5. High fever above 103°F (39.4°C): may indicate secondary infection or autonomic instability requiring immediate emergency medical evaluation

Treatment for 7-OH Use Disorder at Olympic Behavioral Health

Olympic Behavioral Health provides evidence-based, medically supervised treatment for 7-hydroxymitragynine dependence and kratom use disorder through PHP, IOP, and integrated dual diagnosis programming in Lantana, Florida.

Partial Hospitalization Program (PHP)

Olympic Behavioral Health’s PHP delivers structured clinical programming Monday through Sunday, with 6 hours of daily groups on weekdays and 3 hours on weekends, supporting individuals who require intensive intervention for 7-OH dependence without 24-hour inpatient placement.

PHP treatment components directly relevant to 7-OH recovery:

• Daily CBT groups: cognitive behavioral therapy targets the automatic thought patterns that sustain opioid receptor-seeking behavior and reinforce relapse cycles between cravings
• DBT skills training: dialectical behavior therapy provides distress tolerance and emotional regulation skills that directly address the dysregulation that persists through post-acute withdrawal
• Neurofeedback therapy: Olympic Behavioral Health integrates neurofeedback to address cortical hyperarousal and dysregulated dopaminergic reward signaling that characterize opioid use disorder recovery
• Individual therapy: minimum weekly 50-minute sessions with a licensed primary therapist addressing trauma, co-occurring mental health diagnoses, and individualized relapse prevention planning

Intensive Outpatient Program (IOP)

Olympic Behavioral Health’s IOP provides 9 clinical hours per week for individuals stepping down from PHP or managing 7-OH dependence alongside work, family, or school responsibilities.

IOP structure supporting 7-OH recovery:

• Relapse prevention programming: evidence-based skill-building targeting the environmental cues, emotional states, and social contexts that drive 7-OH cravings during sub-acute withdrawal
• EMDR and rapid trauma resolution: trauma-focused modalities addressing underlying PTSD, major depressive disorder, and anxiety disorders that frequently co-occur with opioid use disorder and sustain compulsive use
• Substance-specific psychoeducation groups: covering mu-opioid receptor neurophysiology, tolerance development, withdrawal management expectations, and long-term recovery strategies

Individuals beginning recovery can explore substance abuse treatment programs at Olympic Behavioral Health that integrate psychiatric support with addiction-focused clinical care across all levels.

Psychiatric Support and Dual Diagnosis Care

Olympic Behavioral Health provides board-certified psychiatric evaluation and medication management for individuals presenting with 7-OH dependence alongside co-occurring mental health conditions.

Clinical support components:

• Admission psychiatric evaluation: Dr. Nvari (board-certified psychiatrist) and Sabina (board-certified psychiatric ARNP) conduct DSM-5 dual diagnosis assessments for conditions including major depressive disorder, anxiety disorders, PTSD, and borderline personality disorder
• Trauma track assessment: all incoming patients receive specialized trauma screening to identify co-occurring PTSD and trauma history that frequently underlies opioid receptor-seeking behavior, with EMDR and rapid trauma resolution available for qualifying patients
• Integrated dual diagnosis treatment: individuals with co-occurring psychiatric conditions receive concurrent medication management and addiction-focused group therapy rather than sequential, siloed care

Same-day clinical assessment is available for individuals ready to begin treatment for 7-OH dependence.

Legal Status of 7-OH in the United States

As of April 2026, kratom and 7-hydroxymitragynine remain federally unscheduled, but FDA scheduling recommendations, state emergency rules, and active DEA rulemaking are rapidly narrowing commercial access to concentrated 7-OH products.

Federal Regulatory Actions

The FDA has taken a series of escalating enforcement actions against 7-hydroxymitragynine products, culminating in a formal Schedule I recommendation in July 2025.

Federal actions by date:

• 2012: FDA issues first import restrictions on kratom products entering US ports of entry
• February 2014 (updated February 2025): Import Alert 54-15 authorizes detention of kratom and kratom-containing products without physical examination
• June 2025: FDA issues 7 warning letters to companies marketing concentrated 7-OH products, citing unapproved drug claims and documented public health risk
• July 2025: FDA formally recommends Schedule I classification for concentrated 7-OH products; publishes comprehensive scientific assessment; issues consumer advisory titled “Hiding in Plain Sight”
• 2025 to 2026: US Marshals seize approximately 73,000 units of 7-OH products from Missouri manufacturers
• DEA rulemaking status: a proposed rule, public comment period, and final rulemaking must be completed before 7-OH is formally scheduled; no scheduling date is confirmed as of April 2026

State-Level Bans and Kratom Regulations

Multiple states have enacted laws banning kratom outright or specifically restricting concentrated 7-OH while maintaining different policies toward natural kratom leaf.

State	Status	Detail
Alabama	Full kratom ban	Kratom and alkaloids classified Schedule I under state law
Arkansas	Full kratom ban	Mitragynine and 7-OH classified Schedule I
Indiana	Full kratom ban	Kratom alkaloids classified as synthetic controlled substances
Vermont	Full kratom ban	Kratom classified Schedule I
Wisconsin	Full kratom ban	Synthetic kratom alkaloids classified Schedule I
Washington D.C.	Full kratom ban	Sale and distribution prohibited
Louisiana	Full kratom ban	Effective August 2025
Florida	7-OH-specific emergency rule	Concentrated 7-OH classified Schedule I (August 2025); natural kratom leaf treated separately — see kratom laws in Florida
Ohio	7-OH-specific emergency rule	Emergency rule (December 2025) banning kratom-related products; natural kratom in vegetation form subsequently exempted after legislative clarification
Oklahoma, Oregon, Utah, West Virginia	Kratom Consumer Protection Acts	Regulated but permitted; product testing, labeling, age verification, and seller registration required